Drugs / Allergovac Depot
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01567306 | Oct 2011 → Apr 2013 | allergic disease | Roxall Medicina España S.A | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01564017 Comparator | May 2012 → May 2013 | allergic disease | Roxall Medicina España S.A | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allergovac Depot | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01567306 ↗ |
| Modality | Vaccine | “subcutaneous vaccine” NCT01567306 ↗ |
| Route | Subcutaneous | “Depot sterile suspension for subcutaneous injection” NCT01564017 ↗ |